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BACKGROUND: We sought to determine the extent to which US Preventive Services Task Force (USPSTF) 2012 Grade D recommenda-
tions against prostate-specific antigen screening may have impacted recent prostate cancer disease incidence patterns in the United 
States across stage, National Comprehensive Cancer Network (NCCN) risk groups, and age groups. METHODS: SEER*Stat version 8.3.4 
was used to calculate annual prostate cancer incidence rates from 2010 to 2015 for men aged ≥50 years according to American Joint 
Committee on Cancer stage at diagnosis (localized vs metastatic), NCCN risk group (low vs unfavorable [intermediate or high-risk]), 
and age group (50-74 years vs ≥75 years). Age-adjusted incidences per 100,000 persons with corresponding year-by-year incidence 
ratios (IRs) were calculated using the 2000 US Census population. RESULTS: From 2010 to 2015, the incidence (per 100,000 persons) 
of localized prostate cancer decreased from 195.4 to 131.9 (Ptrend < .001) and from 189.0 to 123.4 (Ptrend < .001) among men aged 50-74 
and ≥75 years, respectively. The largest relative year-by-year decline occurred between 2011 and 2012 in NCCN low-risk disease (IR, 0.77 
[0.75–0.79, P < .0001] and IR 0.68 [0.62–0.74, P < .0001] for men aged 50-74 and ≥75 years, respectively). From 2010-2015, the incidence 
of metastatic disease increased from 6.2 to 7.1 (Ptrend < .001) and from 16.8 to 22.6 (Ptrend < .001) among men aged 50-74 and ≥75 years, 
respectively. CONCLUSIONS: This report illustrates recent prostate cancer “reverse migration” away from indolent disease and toward 
more aggressive disease beginning in 2012. The incidence of localized disease declined across age groups from 2012 to 2015, with the 
greatest relative declines occurring in low-risk disease. Additionally, the incidence of distant metastatic disease increased gradually 
throughout the study period. Cancer 2020;126:717-724. © 2019 American Cancer Society. 
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INTRODUCTION
The prostate-specific antigen (PSA) screening era led to a drastic increase in prostate cancer detection, along with a 
migration toward more indolent disease at diagnosis.1 However, following an October 2011 draft statement, the US 
Preventive Services Task Force (USPSTF) made a formal Grade D recommendation against PSA screening for all men in 
2012 (similar to 2008 Grade D recommendations for men aged ≥75 years)2,3 given questions about screening efficacy 
and concern that screening may lead to overdetection and treatment of indolent disease.4,5 However, consensus on an 
optimal screening paradigm remains sparse, and some specialists and cancer organizations continue to favor routine PSA 
screening for younger, healthy men.6 Moreover, longer follow-up in PSA screening trials has demonstrated the increasing 
efficacy of PSA screening over time given the indolent nature of prostate cancer.7,8 Therefore, in 2018 the USPSTF made 
a Grade C recommendation supporting individualized PSA screening decisions for men aged 55-69 years.8
Using contemporary population-based data, we sought to determine the extent to which 2012 USPSTF recommen-
dations against PSA screening may have impacted recent prostate cancer incidence patterns in the United States across 
stage, National Comprehensive Cancer Network (NCCN)9 risk groups, and age groups.
MATERIALS AND METHODS
To illustrate trends in incidence patterns over time, SEER*Stat version 8.3.4 was used to calculate annual age-adjusted 
incidence rates of prostate cancer from 2010 to 2015 among men aged ≥50 years in the Surveillance, Epidemiology, 
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and End-Results (SEER) 18 Regs Custom Data (with 
additional treatment fields), Nov 2017 Sub (2010-
2015) Database.10 The SEER 18 program collects and 
publishes cancer incidence data from 18 population-
based cancer registries covering approximately 27.8% 
of the US population (based on the 2010 Census).
Trends in rates were compared using Cuzick’s 
test. Incidence rates were calculated by stage at diag-
nosis (American Joint Committee on Cancer [AJCC] 
7th Edition localized disease [T1-T4 N0M0] versus 
AJCC 7th Edition distant metastatic disease [M1]), and 
stratified by age group (50-74 years versus ≥75 years) 
based on USPSTF PSA screening recommendations.2,3 
With the recent inclusion of validated and quality- 
assured PSA data in SEER,11 incidence rates were also 
calculated for localized NCCN-defined risk groups 
(low [PSA <10  ng/mL and cT1-2a  and Gleason ≤6] 
vs unfavorable [intermediate or high-risk] disease [PSA 
>10 ng/mL or cT2b-T4 or Gleason 7-10])9 in patients 
with known PSA, clinical tumor stage, and clinical 
Gleason score. The patient selection included all years 
for which clinical information on NCCN risk factors is 
available in SEER (2010-2015).
Age-adjusted incidence rates and corresponding 
95% confidence intervals (CIs) were expressed per 
100,000 persons using the 2000 US Census standard 
population, with adjustments for delays in reporting. 
To compare incidence rate changes across consecutive 
years, the Tiwari method was applied to define year-
by-year incidence ratios (IRs) with associated 95% CIs 
and P values, using the earlier year as reference (ie, 2010 
[referent] vs 2011).12,13
P values were 2-sided with α  =  .05. The data are 
publicly available and deidentified and are therefore 
considered exempt by the Dana-Farber/Harvard Cancer 
Center institutional review board.
RESULTS
From 2010 to 2015, there was a decrease in the annual 
incidence (per 100,000 persons) of localized prostate can-
cer from 195.4 to 131.9 (Ptrend <  .001) and from 189.0 
to 123.4 (Ptrend  <  .001) among men aged 50-74  years 
and ≥75 years, respectively (Fig. 1, Supporting Table 1). 
Conversely, there was an increase in the incidence of meta-
static disease from 6.2 to 7.1 (Ptrend < .001) and from 16.8 
to 22.6 (Ptrend < .001) among men aged 50-74 years and 
≥75 years, respectively (Fig. 1, Supporting Table 1). There 
was also a decrease in the annual incidence of both local-
ized NCCN low-risk and unfavorable (intermediate/high)-
risk localized prostate cancer from 60.6 to 31.4 and from 
104.2 to 84.3, respectively, among men aged 50-74 years. 
Among men aged ≥75  years, incidence rates decreased 
similarly from 26.1 to 11.6 and from 134.5 to 94.7, 
respectively (all Ptrend < .001) (Fig. 1, Supporting Table 1).
The largest relative year-by-year decline in inci-
dence of localized disease occurred between 2011 and 
2012, regardless of age or risk group (Fig. 2, Supporting 
Table 2). The incidence of low-risk disease began to 
decline in 2012 across age groups, although the decline was 
relatively greater among men aged ≥75 years (incidence 
ratio [IR], 0.68 [95% CI, 0.62-0.74]) compared with 
men aged 50-74 years (IR, 0.77 [95% CI, 0.75-0.79]). 
Notably, the subgroup with the largest relative year-by-year 
decline in incidence observed in this study occurred 
between 2011 and 2012 in low-risk disease among men 
aged ≥75  years (Fig. 2, Supporting Table 2). The inci-
dence of low-risk disease declined in each consecutive 
year from 2012 to 2015 among men aged 50-74  years 
(P < .0001 for all IRs [Fig. 2, Supporting Table 2]). For 
men aged ≥75  years however, incidence rates declined 
from 2012 to 2014 before stabilizing from 2014 to 2015 
(Fig. 2, Supporting Table 2). Overall, from 2010 to 2015 
there was a greater absolute decline in the incidence 
of low-risk disease  among men aged 50-74  years (29.2 
fewer cases per 100,000 men) compared with men aged 
≥75  years (14.5 fewer  cases per 100,000 men) (Fig. 1, 
Supporting Table 1).
The incidence of unfavorable (intermediate/high)-
risk disease also began to decline between 2011 and 2012 
across age groups, although the declines were relatively 
smaller compared with low-risk disease. Declining inci-
dence rates in 2012 were again greater among men aged 
≥75 years (IR, 0.78 [95% CI, 0.75-0.81]) compared with 
men aged 50-74 years (IR, 0.86 [95% CI, 0.84-0.88]). 
Notably, incidence rates declined in consecutive years 
until 2014 (P < .01 for all IRs across age groups) before 
increasing from 2014 to 2015, from 79.3 to 84.3 (IR, 
1.06 [95% CI, 1.04-1.08]) and from 89.0 to 94.7 (IR, 
1.06 [95% CI, 1.02-1.11]) among men aged 50-74 and 
≥75 years, respectively.
Metastatic disease incidence increased incrementally 
such that consecutive year-by-year IRs remained compa-
rable for both age groups, with the exception of increases 
among men aged ≥75 years between 2011 and 2012 (IR, 
1.14 [95% CI, 1.04-1.26]) and between 2014 and 2015 
(IR, 1.13 [95% CI, 1.04-1.23]). However, when compar-
ing 2015 with 2010, there were significant increases in 
metastatic disease across age groups (IR, 1.14 [95% CI, 
1.06-1.23] and IR, 1.34 [95% CI, 1.23-1.47] for men 
aged 50-74 years and ≥75 years, respectively).
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DISCUSSION
Utilizing contemporary population-based incidence 
data, this report illustrates recent prostate cancer 
“reverse migration” away from indolent and toward 
more aggressive presentation in the United States fol-
lowing USPSTF Grade D recommendations against 
PSA screening in 2012 (with a draft statement released 
in October 2011 and an official statement released in 
May 2012). The data demonstrate a significant decline 
in the incidence of localized disease across age groups 
from 2010 to 2015, with the greatest declines observed 
between 2011 and 2012. Notably, the greatest relative 
declines in incidence rates were observed in NCCN low-
risk localized disease, where rates continued to decline 
throughout the study period, whereas the incidence of 
unfavorable (intermediate/high)-risk localized disease 
declined until 2014 before increasing between 2014 
and 2015. Furthermore, there was a slow and gradual 
increase in the incidence of distant metastatic disease 
throughout the study period.
To the best of our knowledge, this is the first study to 
report on population-based incidence trends in localized 
(AJCC 7th edition N0M0) prostate cancer and across the 
NCCN risk groups used to guide clinical management. 
Prior studies were not able to benefit from the recent 
inclusion of validated and quality-assured PSA data in 
SEER and therefore have been limited to describing 
trends in SEER summary stage, which is not used in clin-
ical practice,13,14 or in AJCC M1 disease, which cannot 
describe localized risk group patterns.15 By examining 
incidence rates according to NCCN risk group, these 
findings are not only novel and clinically relevant, they 
are also a more accurate reflection of the impact of 
PSA screening recommendations based on the natural 
history of prostate cancer. Specifically, because 65.7% 
of all localized disease and 94.0% of NCCN low-risk 
disease were PSA screen-detected from 2010 to 2011 in 
SEER (unpublished data), USPSTF recommendations 
against screening would be expected to have an imme-
diate impact on localized disease incidence, with the 
Figure 1. Age-adjusted annual incidence rates (per 100,000 persons using the 2000 US Census standard population) of prostate 
cancer diagnoses in the SEER*Stat U.S. Database stratified by age group (≥75  years vs 50-74  years) for (A) localized disease 
(N0M0), (B) metastatic disease (M1), (C) National Comprehensive Cancer Network (NCCN) low-risk localized disease, and (D) NCCN 
unfavorable (intermediate/high)-risk localized disease. Error bars represent 95% CIs. The unknown NCCN risk group accounts for 
the remaining incidence of localized disease.
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greatest impact on NCCN low-risk localized disease—as 
was demonstrated in this study—presumably through 
the decreased detection of indolent and asymptomatic 
disease. The declines in low-risk disease were a goal of 
USPSTF recommendations against screening. However, 
many men with potentially curable disease may present 
with more advanced and difficult-to-cure disease later 
on, as suggested by the slow increases in metastatic dis-
ease and increasing incidence of unfavorable-risk disease 
between 2014 and 2015.
Figure 2. Incidence ratios comparing consecutive annual age-adjusted incidence rates (with error bars representing 95% CIs) of 
prostate cancer diagnoses in the SEER*Stat U.S. Database stratified by age group (≥75 vs. 50-74 years of age) for (A, B) localized 
disease (N0M0), (C, D) metastatic disease (M1), (E, F) National Comprehensive Cancer Network (NCCN) low-risk localized disease, 
and (G, H) NCCN unfavorable (intermediate/high)-risk localized disease. Error bars represent 95% CIs. Incidence ratios compare 
consecutive year-by-year baselines (2011 vs 2010, 2012 vs 2011, 2013 vs 2012, 2014 vs 2013, 2015 vs 2014).
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Notably, Hu et al15 demonstrated that incidence 
rates of distant metastatic disease among men aged 
≥75 years only increased by less than 1 per 100,000 per-
sons from 2007 to 2013 (after USPSTF recommenda-
tions against PSA screening for men aged ≥75 years in 
2008), while we demonstrate that these rates increased 
by 5.8 per 100,000 from 2010 to 2015. This is likely 
because population increases in de novo metastases may 
not be expected until ≥6  years after development of 
disease in nonscreened individuals based on the natu-
ral history of prostate cancer.16-18 As such, the nonsig-
nificant increases in metastatic disease (by ~1 case per 
100,000 persons per year) for men aged 50-74  years 
between 2010 and 2015 would be expected to similarly 
Figure 2. (Continued).
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continue increasing through 2018. Regardless, pros-
tate cancer is a heterogenous disease, and the missed 
screening of higher-risk cancers, which could progress 
more quickly to symptomatic presentation, may lead 
to increases in metastases at earlier time points at the 
population level. The public health ramifications of a 
trend toward excess metastatic prostate cancer incidence 
would likely include not only greater disease morbidity 
(eg, metastatic bone pain, skeletal-related events) and 
prostate cancer mortality, but also greater treatment- 
related toxicity—most notably from lifelong hormonal 
therapy—and higher overall health care costs.
Additionally, our study demonstrated that the largest 
decrease in localized prostate cancer incidence occurred 
between 2011 and 2012—suggesting that there may have 
been a decline in PSA screening throughout the year of 2012 
Figure 2. (Continued).
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after the highly publicized draft recommendations were 
made public in October 2011.
Overall, our results demonstrate disease “reverse 
migration” away from indolent disease and toward more 
aggressive presentation following 2011-2012 USPSTF 
Grade D recommendations against PSA screening. 
Additional factors that may have contributed to these 
trends include changes in perceptions of PSA screening 
risks and benefits, concern of prostate cancer overdi-
agnosis or overtreatment, and emphasis on informed 
decision-making. Patients with unknown clinical infor-
mation on NCCN risk factors (ie, PSA, Gleason score, 
T stage) were not included in analyses stratified by NCCN 
risk group, which could underestimate overall absolute 
incidence rates within risk groups; notably, there was no 
difference in the completeness of data across the study 
Figure 2. (Continued).
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period, hence there is unlikely to be bias within the 
reported trends in relative ratios across years. This study 
was also limited by lack of SEER data on regional differ-
ences in incidence. Lastly, this study was limited by short 
follow-up, and further studies will be required to assess 
the long-term impact of recommendations on prostate 
cancer incidence and mortality. Furthermore, future 
studies will need to determine whether 2018 USPSTF 
Grade C recommendations again shift the prostate cancer 
landscape.
In conclusion, this report illustrates recent prostate 
cancer “reverse migration” away from indolent disease and 
toward more aggressive disease beginning in 2012. The 
incidence of localized disease declined across age groups 
from 2012 to 2015, with the greatest relative declines 
occurring in low-risk disease. Additionally, the incidence of 
distant metastatic disease gradually increased throughout 
the study period.
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